Bevacizumab and pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer: A multicenter, single-arm phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)

---

Autoria(s): Rochlitz C.; Spirig C.; Ruhstaller T.; Suter T.; Bühlmann M.; Fehr M.; Schönenberger A.; Lerch S.; Mayer M.; Zaman K.

Data(s)	2009
Identificador	http://serval.unil.ch/?id=serval:BIB_B62CAE57AEEA isbn:1527-7755
Idioma(s)	en
Fonte	2009 ASCO Annual Meeting
Tipo	info:eu-repo/semantics/conferenceObject inproceedings